Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Investigation of the Potential Contribution of Dual Orexin Receptor Antagonists to Reduction of Benzodiazepine Receptor Agonist Hypnotics
jRCT1031260386Recruiting
- Start
- Sep 2023
- Countries
- 1
01
Overview
Open-label, single-arm trial in Insomnia, sponsored by none. Primary endpoint: Success rate of switching from benzodiazepine receptor agonists to dual orexin receptor antagonists at 16 weeks. Started Sep 2023; status: recruiting.
02
Conditions
Insomnia
Beyond the preview
Go deeper on jRCT1031260386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031260386.